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Abstract
Background: Patient enrolment into clinical trials is based on oral information and informed consent, which
includes an information sheet and a consent certificate. The written information should be complete, but at the
same time risks being so complex that it may be questioned if a fully informed consent is possible to provide. We
explored patient representatives’ views and perceptions on the written trial information used in clinical cancer trials.
Methods: Written patient information leaflets used in four clinical trials for colorectal cancer were used for the study.
The trials included phase I-III trials, randomized and non-randomized trials that evaluated chemotherapy/targeted
therapy in the neoadjuvant, adjuvant and palliative settings. Data were collected through focus groups and were
analysed using inductive content analysis.
Results: Two major themes emerged: emotional responses and cognitive responses. Subthemes related to the former
included individual preferences and perceptions of effect, while subthemes related to the latter were comprehensibility
and layout. Based on these observations the patient representatives provided suggestions for improvement, which
largely included development of future simplified and more attractive informed consent forms.
Conclusions: The emotional and cognitive responses to written patient information reported by patient representatives
provides a basis for revised formats in future trials and add to the body of information that support use of plain language,
structured text and illustrations to improve the informed consent process and thereby patient enrolment into clinical
trials.
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Background
Enrolment into clinical trials is central to develop, evaluate
and implement new cancer treatments. Respect for patient
autonomy is central in both health care and medical re-
search, but the regulatory codes are particularly strict in
the latter situation. To guarantee autonomy and protect
patients from harm, oral and written clinical trial informa-
tion is provided; thereafter the patient gives an informed
consent to participate [1]. Oral information about study
concept, aims, randomization, risks and benefits and prac-
tical implications is provided by physicians and research
nurses. The patient thereafter receives an informed con-
sent form, which consists of two parts, i.e. an information
sheet and a consent certificate.
Written patient information is typically developed by
study sponsors, who may represent academic researchers
or commercial companies, where after the content is
assimilated to local/regional standards and to meet the
requirements of ethical committees. The World Health
Organization (WHO) provides useful and comprehensive
informed consent form templates for clinical studies
(http://wma.net/en/30publications/10policies/b3/17c.pdf).
The written information is typically extensive and should
cover e.g. the purpose of the research, the type of inter-
vention, participant selection, voluntary participation, in-
formation on trial drug/placebo, procedures and protocol,
treatment alternatives, randomization, additional tests/in-
vestigations, duration, standards and guidelines, side ef-
fects, potential risks and benefits, reimbursements,
confidentiality, sharing of results, contact information,
and the right to refuse or withdraw from the study at any
time without explanation and without compromised
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medical care. The signature on a consent form is aimed to
verify a voluntary decision to participate and to ensure
that the patient understands the risks and benefits linked
to participation. The consent process traditionally covers
all aspects in entirety. The basic principles is to provide a
full and comprehensive picture of potential risks and ben-
efits, but complex information risks reducing the in-
formed consent signature to a legal symbol needed to
initiate treatment [2–4]. Though patients are generally sat-
isfied with the consent process, the understanding of e.g.
study aims, treatment risks and benefits, randomization
and research aspects has been demonstrated to be sub-
optimal [5, 6]. We explored patient representatives’ views
and perceptions of written information used in clinical
cancer trials through focus groups.
Methods
Patient information leaflets
Written information used in four cancer trials for colorec-
tal cancer was used for the study. The studies had com-
pleted accrual and evaluated chemotherapy, targeted
therapy and radiotherapy or combinations of these, repre-
sented phase I-III trials and were performed in different
disease settings, i.e. in the adjuvant, the neo-adjuvant and
the palliative settings (Table 1). The study information
texts varied between 748 and 2075 words and were writ-
ten in Swedish. The names of drugs and companies were
substituted with ‘the drug/treatment regimen’ or ‘the com-
pany’ in brackets.
Informants
Patient representatives were recruited from the two
Swedish patient associations for gastrointestinal diseases
(www.ilco.nu) (www.magotarm.se). Eligibility included
prior colorectal cancer, completed treatment for cancer
and no current colorectal cancer. The 14 informants in-
cluded seven males and seven females with a mean age of
67 years, range 51–77 years, who had been diagnosed with
colorectal cancer 1–8 years prior to the study. The level of
education was primary school in three individuals, limited
further education in four and university studies in five in-
dividuals with lack of information in two individuals. The
informants had experience from different forms of treat-
ment and four of 14 reported participation in a clinical
trial related to their cancer diagnosis. The informants
received an information letter including the texts from the
four selected trials 3–5 days before the focus group inter-
views, resembling the typical time allowed for decision-
making in the clinical setting.
Focus group interviews and analysis
Three separate focus group interviews were performed; one
group with five female participants, one group with five
male participants and group with four participants from
both sexes. The participants were asked to put themselves
in the patients/potential study participants’ perspective.
The focus group discussions led by PD (MD, oncologist
with previous experience from 4 focus group studies) and
CC (PhD, Study Nurse with extensive experience in focus
group studies) who alternated as moderator and registrar.
Each group performed four separate interviews of 30–45
min length on each of the four written trial forms. The in-
terviews was initiated by “I am interested in your opinion
and would like you to describe the text from your point of
view.” To open for suggestions for improvements in the
texts, we asked follow-up questions, such as: “What do you
understand? What do you not understand? At the end of
the focus group discussions the informants were asked
“How would you prefer to have it phrased?” and were in-
vited to provide suggestions for improvements in the infor-
mation leaflets.
The focus group interviews were audio-taped, transcribed
verbatim and analysed using inductive content analysis [7].
Herein, the texts were initially read where after meaning
units were identified through text searches for words, state-
ments and sentences with relevance for the study aims and
perspectives. The distinct meaning units were coded. After
this process of de-contextualisation, the coded meaning
units were compared and condensed. In parallel, the texts
were condensed. Hereafter, two major themes emerged,
under each of which two subthemes were defined. The sug-
gested improvements were included in the analysis, but
were separately analysed and grouped and did not contrib-
ute to the definition of themes and subthemes.
The study was approved by the Ethics Committee of
Lund University (346/2007).
Results
Two major themes were identified, i.e. emotional re-
sponses and cognitive responses. Subthemes related to the
Table 1 Features of the clinical trials and the information leaflets
Trial information leaflets Phase Treatment intention Arms/randomization Words Headlines Medical terms explained/unexplained
A I-II Neoadjuvant 1/- 2075 20 14/53
B III Palliative 2/+ 1090 9 3/50
C I-II Palliative 1/- 1032 13 0/15
D III Adjuvant 2/+ 748 1 3/16
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former included individual preferences and perceptions
of effect, while subthemes related to the latter major
theme were comprehensibility and layout. The suggestions
for improvement provided are separately presented.
Emotional responses
The informants found the first impression of a text to be
important for their motivation to continue reading and to
assimilate the information. Individual preferences were
frequently referred to and the informants reflected on
their different perceptions, which were viewed to differ
also in relation to the disease situation, i.e. adjuvant/neo-
adjuvant versus metastatic, as well as to the type of treat-
ment discussed since the risk-benefit perception is highly
variable between individuals. The informants expressed
that the content evoked emotions and stress, particularly
related to the decision to participate and to potential side
effects. A male informant associated signing the patient
information to signing a real estate contract. He found this
frightening and expressed a need to learn about the poten-
tial benefits of the experimental treatment to overcome
feelings of reluctance and to raise motivation to learn
about the purpose of the trial.
…I would rather read about side-effects than risks,
because you don’t want to take risks (female group,
informant 6, trial A)
… so that you can check off yourself… now I’ve done
this part of the treatment and now I’m going to go into
the next phase… How long does this actually take? …
This also gives security. (Female group, informant 9,
trial D)
Cognitive responses
Comprehensibility and layout were repeatedly referred to
and were closely related. Compared with other informa-
tion materials, the trial information was found to be less
attractive and failed to raise an interest in the subject. The
informants stressed access to information with a focus on
layout, which was perceived to be important for compre-
hension. The informants repeatedly expressed difficulties
to grasp the core contents, in particular related to medical
terms and complex words. When the informants encoun-
tered difficult sections, they either interrupted reading to
figure out the meaning, or skipped the section despite un-
certainty about the content. The informants asked for in-
formation that was structured and easy to access and
comprehend, such as including summaries of key con-
tents, e.g. aims, treatment plan and the risk/benefit, and
inclusion of graphic elements and use of bullets. Relevant
excerpts are presented below.
I think that the text is far too heavy. If I’d gotten it in
my hand I think I would have read one page and then
not read any more. I just wouldn’t have managed.
(Male group, informant 13, trial A)
… (if there are few headings) you have to read through
all the text to see if there’s anything that’s important.
(Male group, informant 10, trial D)
It’s probably always easier to assimilate if you get
something like this with colour or some little extra
picture or something in the text. (Female group,
informant 9, trial D)
… it surprises me that when you spend so much time
and money and work on a clinical trial, that you don’t
consider beforehand how the patients will perceive
this… (Male group, informant 12, trial D)
You should emphasize texts and set it in different
kinds of letters…use bold text and italics about what’s
important and what you want to emphasize…You
catch the eye right away.(Male group, informant 13,
trial C)
A picture says an enormous amount. It can be
something drawn or a diagram. (Male group,
informant 13, trial B)
Suggestions for improvement
The informants suggested a total of 44 improvements data
not shown. Age, sex and educational level influenced the
number of suggestions, with an underrepresentation among
the elderly (9 % from informants >75 years), females (36 %
from females) and individuals with less education (33 %
from individuals without university degrees). Layout sug-
gestions predominated (24 of 44). Suggestions related to an
increased appeal (i.e. layout, graphics and accessibility) and
better comprehensibility (i.e. structured contents using
headings, sections, colours and bullet points and use of
plain language). Additional requests related to explanation
of medical terms, refined descriptions of treatments and in-
vestigations and detailed data on drug characteristics and
managements of side effects.
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Discussion
Focus group data based on patient representatives’ views
on written clinical trial information identified emotional
responses and cognitive responses as major themes with
subthemes related to emotions and side effects as well as
comprehension and layout. Written patient information
should be complete and comprehensive, which at the
same times makes it extensive and complex. Templates
for informed consent forms are available, but focus on
content and completeness rather than presentation format
and comprehensibility. Our findings support greater atten-
tion to patients’ perspectives, reactions and responses to
this information [8]. The identification of emotional
responses is supported also by data that suggest that infor-
mation in plain language increase satisfaction and de-
crease anxiety and that optimal design needs to take
measures of patient satisfaction and health literacy into
account [9–11].
Cognitive responses related to comprehension and lay-
out. The layout of the patient information forms studied
was representative, but none of the forms contained illus-
trations or were perceived to have an attractive layout.
The informants identified e.g. poor structure, missing
headings, lack of illustrations and a use of medical terms
that were not explained. The informants underscored the
importance of a logical structure for their ability to under-
stand the contents, e.g. related to sequence of different
therapies. The length was not identified as an obstacle,
but a clear structure, with e.g. sections, headings, bullet
points and key messages, was perceived as important. The
informants underscored the importance of graphical ele-
ments, which represent the preferred mode of information
for many individuals.
Consent forms are generally constructed by medical
professionals, who may consider correct and complete in-
formation more important than layout. However, nine out
of ten prefer graphic design and illustrations, which may
be particularly relevant for individuals with poor reading
skills [12–16]. These different preference have received
less attention in medical texts than in e.g. teaching
materials and in multi-media presentations [17–19].
Educational research demonstrates that information
perceived as attractive increases its potential and read-
ability [10, 20]. Plain language, short sentences, dia-
grams, pictures and bullet points have also recently in a
randomized study been shown to effectively enhance
understanding of consent forms irrespective of health
literacy level [21]. Collaboration between investigators
and patient representatives has been suggested to im-
prove participant comprehension and satisfaction [6].
Hence, development of future simplified and more at-
tractive informed consent forms require collaboration
between investigators, regulatory agents, professional
writers, illustrators and patient representatives.
Optimally, patient representatives should be involved in
the development of information materials prior to the
study. Our study used finalized information forms, which
had been used to include a considerably number of patients
into the trials in question. The colorectal cancer study in-
formation sheets used were compared to a guide for written
trial information that we developed in collaboration with
breast cancer representatives [22]. Only 11–15 of the 52 de-
fined issues in this guide were met in each of the four colo-
rectal cancer information sheets analysed. Themes asked
for that were not included in any of the studies included
background data for the drugs used in the trials, a handy
format and an attractive layout and inclusion of illustra-
tions. Themes that were partly met, but frequently asked
for, included descriptions of how side-effects are managed,
separate time estimated for the different study procedures
and a structured format with clear section and headings in
order to facilitate orientation in a long and complex text.
This observation is also supported by Kundapura et al. [23]
who found that 70 % of the informed consent forms devi-
ated from the regulations defined.
A number of factors, e.g. perceived personal benefit,
chance for cure/clinical benefit, practical issues and altru-
istic perspectives, influence patients’ decisions to partici-
pate in clinical trials, but knowledge about how these
issues affect decision-making is limited [24, 25]. Personal
interaction, discussions and feedback may positively im-
prove readability and influence understanding. In this
process decision aids for patients and guidelines for pro-
fessionals may improve emotional as well as cognitive re-
sponses to clinical trial information [26–28].
Conclusion
Patient representatives identify multiple shortcomings in
written information used in clinical cancer trials. The infor-
mation was perceived as unattractive, incomplete and partly
difficult to read with a lack of structure and illustrations.
The themes identified-emotional and cognitive responses-
may be relevant to consider in the future development of
written information materials. Our findings suggest that
relatively simple improvements could increase satisfaction
and potentially improve the important process of enrolling
cancer patients into clinical trials.
Practice implication
 Emotional and cognitive responses are described
among patient representatives when asked to reflect
upon written information for clinical cancer trials.
 Simple improvement related to e.g. structure and
illustrations are suggested to improve perception
and suggest that future information should be
developed with the aid from professional writers,
illustrators and patient representatives.
Dellson et al. BMC Health Services Research  (2016) 16:36 Page 4 of 5
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Two of the authors (PD and CC) collected data and performed the analysis.
All three authors (PD, MN and CC) contributed to the concept and design
the study, drafted the manuscript and approved it. All authors read and
approved of the final manuscript.
Acknowledgements
We would like to thank the focus group participants for their contributions
and the principal investigators for permission to use the informed consent
forms. Financial support was granted by the Nilsson Cancer Fund and the
Region Skane Research Fund.
Author details
1Division of Oncology and Pathology, Institute of Clinical Sciences, Lund
University, Medicon Village, Scheelevägen 8, S-22381 Lund, Sweden. 2Clinical
Research Centre, Hvidovre Hospital, University of Copenhagen, Kettegård allé
30, 2650 Hvidovre, Copenhagen, Denmark.
Received: 9 March 2015 Accepted: 13 January 2016
References
1. World Medical Associations Declaration of Helsinki, Ethical Principles for
Medical Research Involving Human Subjects; 1964/2013. http://wma.net/en/
30publications/10policies/b3/17c.pdf.
2. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in
cancer clinical trials: a cross-sectional survey. Lancet. 2001;358(9295):1772–7.
3. Griffin JM, Struve JK, Collins D, Liu A, Nelson DB, Bloomfield HE. Long term
clinical trials: how much information do participants retain from the
informed consent process? Contemp Clin Trials. 2006;27(5):441–8.
4. Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the
decisions of cancer clinical trial participants to enter research studies: factors
associated with informed consent, patient satisfaction, and decisional regret.
Patient Educ Couns. 2006;63(1–2):104–9.
5. Bergenmar M, Johansson H, Wilking N. Levels of knowledge and perceived
understanding among participants in cancer clinical trials - factors related to
the informed consent procedure. Clin Trials. 2011;8(1):77–84.
6. Jefford M, Moore R. Improvement of informed consent and the quality of
consent documents. Lancet Oncol. 2008;9(5):485–93.
7. Silverman D. Doing qualitative research. A practical handbook. London:
Sage; 2013.
8. Sand K, Loge JH, Berger O, Gronberg BH, Kaasa S. Lung cancer patients’
perceptions of informed consent documents. Patient Educ Couns. 2008;
73(2):313–7.
9. Davis TC, Holcombe RF, Berkel HJ, Pramanik S, Divers SG. Informed consent
for clinical trials: a comparative study of standard versus simplified forms.
J Natl Cancer Inst. 1998;90(9):668–74.
10. Grossman SA, Piantadosi S, Covahey C. Are informed consent forms that
describe clinical oncology research protocols readable by most patients and
their families? J Clin Oncol. 1994;12(10):2211–5.
11. Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, et al. Randomized,
controlled trial of an easy-to-read informed consent statement for clinical
trial participation: a study of the Eastern Cooperative Oncology Group.
J Clin Oncol. 2003;21(5):836–42.
12. Clark RC, Lyons C. Graphics for learning: Proven guidlines for planning,
designing, and evaluating visual in training matarials. Hoboken: Wiley; 2010.
13. Frost MH, Thompson R, Thiemann KB. Importance of format and design in
print patient information. Cancer Pract. 1999;7(1):22–7.
14. Doak CC, Root JH. Teaching patient with low literacy skills. 2nd ed.
Philadelphia: J.B. Lippincott Company; 1996.
15. Austin PE, Matlack II R, Dunn KA, Kesler C, Brown CK. Discharge instructions:
do illustrations help our patients understand them? Ann Emerg Med. 1995;
25(3):317–20.
16. Delp C, Jones J. Communicating information to patients: the use of cartoon
illustrations to improve comprehension of instructions. Acad Emerg Med.
1996;3(3):264–70.
17. NHS. Patient Information Centre. 2015; Available from http://ec.europa.eu/
health/files/eudralex/vol-2/c/2009_01_12_readability_guidline_final_en.pdf.
18. Shneerson C, Windle R, Cox K. Innovating information-delivery for potential
clinical trials participants. What do patients want from multi-media
resources? Patient Educ Couns. 2013;90(1):111–7.
19. European Comission, E. Guideline on readability of the labelling and
package leaflet of medical products for human use. 2009. Available from
http://www.nhs.uk/video/pages/clinical-trial.aspx. 2015.
20. Barry A. Visual inteligence: perception, image, and manipulation in visual
communication. New York: State University of New York Press; 1997.
21. Kim EJ, Kim SH. Simplification improves understanding of informed consent
information in clinical trials regardless of health literacy level. Clin Trials.
2015;12(3):232–6.
22. Dellson P, Nilbert M, Bendahl PO, Malmstrom P, Carlsson C. Towards
optimised information about clinical trials; identification and validation of
key issues in collaboration with cancer patient advocates. Eur J Cancer Care
(Engl). 2011;20(4):445–54.
23. Kundapura SV, Poovaiah T, Ghooi RB. The big Cs of the informed consent form:
compliance and comprehension. Indian J Med Ethics. 2013;10(4):232–7.
24. Fayter D, McDaid C, Eastwood A. A systematic review highlights threats to
validity in studies of barriers to cancer trial participation. J Clin Epidemiol.
2007;60(10):990–1001.
25. Enzinger AC, Zhang B, Weeks JC, Prigerson HG. Clinical trial participation as
part of end-of-life cancer care: associations with medical care and quality of
life near death. J Pain Symptom Manage. 2014;47(6):1078–90.
26. Flory J, Emanuel E. Interventions to improve research participants’
understanding in informed consent for research: a systematic review.
JAMA. 2004;292(13):1593–601.
27. Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F, et al.
Improving informed consent: pilot of a decision aid for women invited to
participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expect.
2008;11(3):252–62.
28. Dear RF, Barratt AL, Askie LM, Butow PN, McGeechan K, Crossing S, et al.
Impact of a cancer clinical trials web site on discussions about trial
participation: a cluster randomized trial. Ann Oncol. 2012;23(7):1912–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dellson et al. BMC Health Services Research  (2016) 16:36 Page 5 of 5
